Serpins (serine protease inhibitors or classified inhibitor family I4) are the largest and most broadly distributed superfamily of protease inhibitors \[[@B1],[@B2]\]. Serpin-like genes have been identified in animals, poxviruses, plants, bacteria and archaea, and over 1,500 members of this family have been identified to date. Analysis of the available genomic data reveals that all multicellular eukaryotes have serpins: humans, *Drosophila*, *Arabidopsis thaliana* and *Caenorhabditis elegans*have 36, 13, 29, and about 9 serpin-like genes, respectively \[[@B1],[@B3]\]. In contrast, serpins in prokaryotes are sporadically distributed and most serpin-containing prokaryotes have only a single serpin gene \[[@B4]\]. The majority of serpins inhibit serine proteases, but serpins that inhibit caspases \[[@B5]\] and papain-like cysteine proteases \[[@B6],[@B7]\] have also been identified. Rarely, serpins perform a non-inhibitory function; for example, several human serpins function as hormone transporters \[[@B8]\] and certain serpins function as molecular chaperones \[[@B9]\] or tumor suppressors \[[@B10]\]. A phylogenetic study of the superfamily divided the eukaryotic serpins into 16 \'clades\' (termed A-P) \[[@B1]\]. The proteins are named SERPINXy, where X is the clade and y is the number within that clade; many serpins also have alternative names from before this classification was proposed.

Serpins are relatively large molecules (about 330-500 amino acids) in comparison with protease inhibitors such as basic pancreatic trypsin inhibitor (BPTI, which is about 60 amino acids) \[[@B11]\]. Over 70 serpin structures have been determined, and these data, along with a large amount of biochemical and biophysical information, reveal that inhibitory serpins are \'suicide\' or \'single use\' inhibitors that use a unique and extensive conformational change to inhibit proteases \[[@B12]\]. This conformational mobility renders serpins heat-labile and vulnerable to mutations that promote misfolding, spontaneous conformational change, formation of inactive serpin polymers and serpin deficiency \[[@B13]\]. In humans, several conformational diseases or \'serpinopathies\' linked to serpin polymerization have been identified, including emphysema (SERPINA1 (antitrypsin) deficiency) \[[@B14]\], thrombosis (SERPINC1 (antithrombin) deficiency) \[[@B15]\] and angio-edema (SERPING1 (C1 esterase inhibitor) deficiency) \[[@B16]\]. Accumulation of serpin polymers in the endoplasmic reticulum of serpin-secreting cells can also result in disease, most notably cirrhosis (SERPINA1 polymerization) \[[@B14]\] and familial dementia (SERPINI1 (neuroserpin) polymerization) \[[@B17]\]. Other serpin-related diseases are caused by null mutations or (rarely) point mutations that alter inhibitory specificity or inhibitory function \[[@B18]\]. Here, we summarize the evolution, structure and mechanism of serpin function and dysfunction.

Broad organization of the serpin superfamily
============================================

Serpins appear to be ubiquitous in multicellular higher eukaryotes and in the poxviridae pathogens of mammals. In humans, the two largest clades of the 36 serpins that have been identified are the extracellular \'clade A\' molecules (thirteen members found on chromosomes 1, 14 and X) and the intracellular \'clade B\' serpins (thirteen members on chromosomes 18 and 6) \[[@B3]\].

Recent bioinformatic and structural studies have also identified inhibitory serpins in the genomes of certain primitive unicellular eukaryotes (such as *Entamoeba histolytica*\[[@B19]\]) as well as prokaryotes \[[@B4],[@B20]\]. No fungal serpin has been identified to date, and the majority of prokaryotes do not contain clearly identifiable serpin-like genes. Phylogenetic analyses have found no evidence for horizontal transfer \[[@B1],[@B21]\], and it is instead suggested that serpins are ancient proteins and that most prokaryotes have lost the requirement for serpin-like activity \[[@B4]\].

Functional diversity of serpins
===============================

Inhibitory serpins have been shown to function in processes as diverse as DNA binding and chromatin condensation in chicken erythrocytes \[[@B22],[@B23]\], dorsal-ventral axis formation and immunoregulation in *Drosophila*and other insects \[[@B24],[@B25]\], embryo development in nematodes \[[@B26]\], and control of apoptosis \[[@B5]\].

In humans, the majority (27 out of 36) of serpins are inhibitory (Table [1](#T1){ref-type="table"}). Clade A serpins include inflammatory response molecules such as SERPINA1 (antitrypsin) and SERPINA3 (antichymotrypsin) as well as the non-inhibitory hormone-transport molecules SERPINA6 (corticosteroid-binding globulin) and SERPINA7 (thyroxine-binding globulin). Clade B includes inhibitory molecules that function to prevent inappropriate activity of cytotoxic apoptotic proteases (SERPINB6, also called PI6, and SERPINB9, also called PI9) and inhibit papain-like enzymes (SERPINB3, squamous cell carcinoma antigen-1) as well as the non-inhibitory molecule SERPINB5 (maspin). SERPINB5 does not undergo the characteristic serpin-like conformational change and functions to prevent metastasis in breast cancer and other cancers through an incompletely characterized mechanism \[[@B10],[@B27]\]. The roles of several other well characterized human serpins are also summarized in Table [1](#T1){ref-type="table"}.

Numerous important branches of the serpin superfamily remain to be functionally characterized. For example, although plants have a large number of serpin genes, the function of plant serpins remains obscure. Studies *in vitro*clearly show that plant serpins can function as protease inhibitors \[[@B28]\], but plants lack close relatives of chymotrypsin-like proteases, which would be the obvious targets for these serpins. Thus, it has been suggested that plant serpins may be involved in inhibiting proteases in plant pathogens; for example, they may be targeting digestive proteases in insects \[[@B29]\]. One study convincingly demonstrated a close inverse correlation between the upregulation of *Cucurbita maxima*(squash) phloem serpin-1 (CmPS) and aphid survival \[[@B30]\]. Feeding experiments *in vitro*showed, however, that purified CmPS did not affect insect survival \[[@B30]\]. Together, these data suggest that rather than directly interacting with the pathogen, plant serpins, like their insect counterparts, may have a role in the complex pathways involved in upregulating the host immune response.

Similarly, the role of serpins in prokaryotes remains to be understood; again, these molecules are capable of inhibitory activity *in vitro*\[[@B20]\], but their targets *in vivo* and their function remain to be characterized. Interestingly, several inhibitory prokaryote serpins are found in extremophiles that live at elevated temperatures (for example, *Pyrobaculum aerophilum*, which lives at 100°C); these serpins use novel strategies to function as inhibitors at elevated temperatures while resisting inappropriate conformational change \[[@B4],[@B20],[@B31]\].

Structural biology of the serpins and the mechanism of protease inhibition
==========================================================================

Serpins are made up of three β sheets (A, B and C) and 8-9 α helices (termed hA-hI). Figure [1a](#F1){ref-type="fig"} shows the native structure of the archetypal serpin SERPINA1 \[[@B32]\]. The region responsible for interaction with target proteases, the reactive center loop (RCL), forms an extended, exposed conformation above the body of the serpin scaffold. The remarkable conformational change characteristic of inhibitory serpins is depicted in Figure [1d](#F1){ref-type="fig"}; the structure of SERPINA1 with its RCL cleaved \[[@B33]\] shows that, following proteolysis, the amino-terminal portion of the RCL inserts into the center of β-sheet A to form an additional (fourth) strand (s4A). This conformational transition is termed the \'stressed (S) to relaxed (R) transition\', as the cleavage of native inhibitory serpins results in a dramatic increase in thermal stability. Native serpins are therefore trapped in an intermediate, metastable state, rather than their most stable conformation, and thus represent a rare exception to Anfinsen\'s conjecture, which predicts that a protein sequence will fold to a single structure that represents the lowest free-energy state \[[@B34]\].

Serpins use the S-to-R transition to inhibit target proteases. Figure [1b](#F1){ref-type="fig"} shows the structure of an initial docking complex between a serpin and a protease (SERPINA1 and trypsin \[[@B35],[@B36]\]) and Figure [1c](#F1){ref-type="fig"} shows the final serpin-enzyme complex \[[@B12]\]. These structural studies \[[@B12],[@B35],[@B36]\], combined with extensive biochemical data, revealed that RCL cleavage and subsequent insertion is crucial for effective protease inhibition. In the final serpin-protease complex, the protease remains covalently linked to the serpin, the enzyme being trapped at the acyl-intermediate stage of the catalytic cycle. Structural comparisons show that the protease in the final complex is severely distorted in comparison with the native conformation, and that much of the enzyme is disordered \[[@B12]\]. In addition, a fluorescence study demonstrated that the protease was partially unfolded in the final complex \[[@B37]\]. These conformational changes lead to distortion at the active site, which prevents efficient hydrolysis of the acyl intermediate and the subsequent release of the protease. These data are consistent with the observation that buried or cryptic cleavage sites within trypsin become exposed following complex formation with a serpin \[[@B38]\]. It is possible that cleavage of such cryptic sites within the protease occurs *in vivo*and thus results in permanent enzyme inactivation. The absolute requirement for RCL cleavage, however, means that serpins are irreversible \'suicide\' inhibitors.

A major advantage of the serpin fold over small protease inhibitors such as BPTI is that the inhibitory activity of serpins can be exquisitely controlled by specific cofactors. For example, human SERPINC1 (antithrombin) is a relatively poor inhibitor of the proteases thrombin and factor Xa until it is activated by the cofactor heparin \[[@B39]\]. Structural studies of SERPINC1 highlight the molecular basis for heparin function. Figure [2a](#F2){ref-type="fig"} shows the structure of native SERPINC1. Here, we use the convention of Schechter and Berger, in which residues on the amino-terminal side of the cleavage site (P1/P1\') are termed P2, P3, and so on, and those carboxy-terminal are termed P2\', P3\', and so on; corresponding subsites in the enzyme are termed S1, S2, and so on \[[@B40]\]. The RCL is partially inserted into the top of the 3 sheet; the residue (P1-Arg) responsible for docking into the primary specificity pocket (S1) of the protease is relatively inaccessible to docking with thrombin, as it is pointing towards and forming interactions with the body of the serpin \[[@B41],[@B42]\]. Figure [2b](#F2){ref-type="fig"} illustrates the ternary complex between SERPINC1, thrombin and heparin \[[@B43]\]. Upon interaction with a specific heparin pentasaccharide sequence present in high-affinity heparin, SERPINC1 undergoes a substantial conformational rearrangement whereby the RCL is expelled from β-sheet A and the P1 residue flips to an exposed protease-accessible conformation \[[@B44]-[@B46]\]\]. In addition to loop expulsion and P1 exposure, long-chain heparin can bind both enzyme and inhibitor and thus provides an additional acceleration of the inhibitory interaction. Several other serpins, including SERPIND1 (heparin cofactor II), also use cofactor binding and conformational change to achieve exquisite inhibitory control \[[@B47]\].

Structural studies on prokaryote and viral serpins have revealed several interesting variations of the serpin scaffold. Viral proteins are often \'stripped down\' to a minimal scaffold in order to minimize the size of the viral genome. Consistent with this requirement, the structure of the viral serpin crmA, one of the smallest members of the serpin superfamily \[[@B48],[@B49]\], shows that it lacks helix hD. More recently, the structure of the prokaryote serpin thermopin from *Thermobifida fusca*revealed the absence of helix hH \[[@B20],[@B31]\]. These studies also showed that thermopin contains a 4 amino-acid insertion at the carboxyl terminus that forms extensive interactions with conserved residues at the top of β-sheet A (called the \'breach\'; see later); biophysical data suggest that this region is important for proper and efficient folding of this unusual serpin.

The major conformational change that occurs within both the protease and the serpin as a result of serpin-enzyme complex formation provides an elegant mechanism for cells to specifically detect and clear inactivated serpin-protease complexes. Several studies have shown that the low density lipoprotein-related protein (LRP) specifically binds to and promotes internalization of the final complexes SERPINC1-thrombin, SERPIND1-thrombin and SERPINA1-trypsin. In contrast, native or cleaved serpin alone are not internalized \[[@B50]\]. Additionally, recent studies on SERPINI1 show that both SERPINI1-tissue plasminogen activator complexes and native SERPINI1 are internalized in an LRP-dependent manner. However, while SERPINI1-tissue plasminogen activator complexes can bind directly to LRP, native SERPINI1 requires the presence of an (as yet unidentified) cofactor \[[@B51]\]. The structural basis for interaction of LRP with serpin-enzyme complexes and the subsequent intracellular signaling response remain to be fully understood. It is clear, however, that native serpins and serpin-enzyme complexes can induce powerful responses such as cell migration in an LRP-dependent manner \[[@B52]\].

Inactivation of serpins: latency, polymerization, deficiency and disease
========================================================================

The metastability of serpins and their ability to undergo controlled conformational change also renders these molecules susceptible to spontaneous conformational rearrangements. Most notably, the serpin SERPINE1 (plasminogen activator inhibitor-1) uses spontaneous conformational change to control inhibitory activity \[[@B53]\]. Structural and biochemical studies show that, in the absence of the cofactor vitronectin, native SERPINE1 (Figure [3a](#F3){ref-type="fig"}) rapidly converts to a latent inactive state (Figure [3b](#F3){ref-type="fig"}). The transition to latency is accompanied by insertion of the RCL into β-sheet A, where it cannot interact with the target protease. Interestingly, the structure of SERPINE1 in complex with the somatomedin B domain of vitronectin \[[@B54]\] shows that the cofactor-binding site on SERPINE1 is located in a similar region to the heparin-binding site of SERPINC1 (on and around helices hD and hE; Figure [3c](#F3){ref-type="fig"}). Whereas heparin promotes conformational change in SERPINC1, however, vitronectin prevents conformational change in SERPINE1. Several other serpins, including SERPINC1, have been shown to spontaneously undergo the transition to the latent state, and it is suggested that this may be an important control mechanism \[[@B55]\].

Although the transition to latency could be an important control mechanism in at least one serpin, an alternative spontaneous conformational change, serpin polymerization, results in deficiency and disease (or serpinopathy) \[[@B14],[@B56]\]. Serpin polymerization is postulated to occur via a domain-swapping event whereby the RCL of one molecule docks into β-sheet A of another to form an inactive long-chain serpin polymer (Figure [4a, b](#F4){ref-type="fig"}) \[[@B14],[@B57]-[@B59]\]. Several important human serpin variants result in polymerization, the best studied and most common of which is the Z allele (Glu342Lys) of SERPINA1 \[[@B14]\]. Here, failure to properly control the activity of neutrophil elastase (the inhibitory target of SERPINA1) in the lung during the inflammatory response results in the destruction of lung tissue, leading to emphysema. Furthermore, in individuals homozygous for the Z-variant, the accumulation of serpin aggregates or polymers in the endoplasmic reticulum of anti-trypsin-producing cells, the hepatocytes, can eventually result in cell death and liver cirrhosis \[[@B14]\]. Similarly, mutation of SERPINI1 results in the formation of neural inclusion bodies and in the disease \'familial encephalopathy with neuroserpin inclusion bodies\' (FENIB) \[[@B17],[@B60],[@B61]\].

In addition to promoting polymerization, several serpin mutations have been identified that promote formation of a disease-linked latent state. Notably, a mutation in SERPINC1, the wibble variant (Thr85Met), results in formation of large amounts of circulating latent SERPINC1 (about 10% of total SERPINC1) \[[@B55]\]. An alternative \'half-way house\' conformation of SERPINA3, termed δ, has also been identified (Figure [4c](#F4){ref-type="fig"}) \[[@B62]\]. The structure of δ-SERPINA3 also highlights the extraordinary flexibility of the serpin scaffold: in this conformation the RCL is partially inserted into β-sheet A and helix hF has partially unwound and inserted into the base of β-sheet A, completing the β-sheet hydrogen bonding (Figure [4c](#F4){ref-type="fig"}). Finally, the promiscuity of β-sheet A is highlighted by the ability of this region to readily accept short peptides: several structural and biochemical studies have demonstrated that peptides can bind to β-sheet A and induce the S-to-R transition (Figure [4d](#F4){ref-type="fig"}).

Valuable insights into the mechanism of serpin function have been gleaned from the structural location of variants that promote serpin instability \[[@B18],[@B63]\]. The majority of serpinopathy-linked mutations (including antitrypsin Siiyama \[[@B64]\] and Mmalton \[[@B65]\], antithrombin wibble \[[@B55]\] and δ-SERPINA3 \[[@B62]\]) cluster in the center of the serpin molecule, underneath β-sheet A, in a region termed the shutter (marked on Figure [1a](#F1){ref-type="fig"}). Interestingly, Glu342, the position mutated in the Z allele of SERPINA1, is located at the breach, which is just above the shutter at the top of β-sheet A. This portion of the molecule is the point of initial RCL insertion. It is suggested that destabilization of β-sheet A in either the shutter or the breach is sufficient to favor the transition to a polymeric or latent state over maintenance of the monomeric metastable native state \[[@B14]\]. Interestingly, analysis of conserved residues in the serpin superfamily also reveals a striking distribution of highly conserved residues stretching down the center of β-sheet A from the breach to the base of the molecule \[[@B1]\].

Unsurprisingly, given the important proteolytic processes they control, simple deficiencies such as those caused by null mutations of a large number of human serpins are linked to disease (some of these are summarized in Table [1](#T1){ref-type="table"}). Interestingly, however, several (rare) mutations have been identified that do not promote instability but instead interfere with the ability of the serpin to interact correctly with proteases. These include the Enschede variant of SERPINF2 \[[@B66]\], in which insertion of an additional alanine in the RCL results in predominantly substrate-like (rather than inhibitory) behavior upon interaction with a protease. Mutations that alter serpin specificity can also have a devastating effect. For example, the Pittsburgh variant of SERPINA1 (antitrypsin) is an effective thrombin inhibitor as a result of mutation of the P1 methionine to an arginine \[[@B67]\]. The carrier of this variant died of a fatal bleeding disorder in childhood.

Our knowledge of the functional biochemistry and cell biology of serpins has been shaped by extensive contributions from structural biology and genomics. The structure of six different serpin conformations, together with analysis of numerous different dysfunctional serpin variants, has allowed the characterization of a unique conformational mechanism of protease inhibition. These data highlight the intrinsic advantages as well as the dangers of structural complexity in protease inhibitors. On the one hand, conformational mobility provides an inherently controllable mechanism of inhibition. On the other, uncontrolled serpin conformational change may result in misfolding and the development of specific serpinopathies. Serpins thus join a growing number of structurally distinct molecules that can misfold and cause important degenerative diseases, such as prions, polyglutamine regions of various proteins and the amyloid proteins that form inclusions in Alzheimer\'s disease. While the mechanism of serpin function is now structurally well characterized, the precise role and biological target of many serpins remains to be understood.
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![The structure and mechanism of inhibitory serpins. **(a)**The structure of native SERPINA1 (Protein Data Bank (PDB) code 1QLP) \[32\]. The A sheet is in red, the B sheet in green and the C sheet in yellow; helices (hA-hI) are in blue. The reactive center loop (RCL) is at the top of the molecule, in magenta. The position of the breach and the shutter are labeled and the path of RCL insertion indicated (magenta dashed line). Both of these regions contain several highly conserved residues, many of which are mutated in various serpinopathies. **(b)**The Michaelis or docking complex between SERPINA1 and inactive trypsin (PDB code 1OPH) \[36\], with the protease (multicolors) docked onto the RCL (magenta). Upon docking with an active protease (b), two possible pathways are apparent. **(c)**The final serpin enzyme complex (PDB code 1EZX \[12\]). The serpin has undergone the S to R transition, and the protease hangs distorted at the base of the molecule. **(d)**The structure of cleaved SERPINA1 is shown (PDB code 7API) \[93\]) with the RCL (magenta) forming the fourth strand of β-sheet A. The result of serpin substrate-like behavior can be seen where the protease has escaped the conformational trap, leaving active protease and inactive, cleaved serpin. Certain serpin mutations, particularly non-conservative substitutions within the hinge region of the RCL, result in substrate-like, rather than inhibitory, behavior \[94\].](gb-2006-7-5-216-1){#F1}

![Modulation of serpin conformation by cofactors. **(a)**The structure of native SERPINC1 (PDB code 2ANT) \[95\]. The partial insertion of the RCL (two residues) into the top of β-sheet A is circled, and the position of the P1 residue is shown (magenta spheres). **(b)**The structure of the ternary complex between SERPINC1, inactive thrombin (the Ser195Ala mutant) and a synthetic long-chain heparin construct (PDB code 1TB6) \[43\]. A specific high-affinity pentasaccharide (green) on the heparin interacts with the heparin-binding site on SERPINC1 (on and around helix hD) and promotes expulsion of the RCL (blue arrow) and rearrangement of the P1 residue (magenta spheres).](gb-2006-7-5-216-2){#F2}

![Spontaneous conformational change in serpins. **(a)**Structure of native SERPINE1 (PDB code 1B3K) \[96\]. The RCL is in magenta and strand s1c of β-sheet C is in yellow. **(b)**The structure of latent SERPINE1 (PDB code 1DVN) \[53,97\], which can form by spontaneous conversion from the native protein. The RCL (magenta) is inserted into β-sheet A. In order to enable full insertion of the RCL, s1C of β-sheet C (pale yellow) has peeled off. In addition, conformational change in the strands s3C and s4C (pale green) is indicated. **(c)**Structure of SERPINE1 (blue) in complex with the somatomedin B domain (green) of vitronectin (PDB code 1OC0) \[54\]. The interaction with vitronectin locks SERPINE1 in the native, active conformation.](gb-2006-7-5-216-3){#F3}

![Structure of serpin polymers and other inactive conformers. **(a)**Schematic diagram of domain swapping in serpins; the RCL of one molecule (magenta loop), is docked into β-sheet A (black lines) of the next (only four strands of β-sheet A are shown). **(b)**Structure of a cleaved serpin polymer (PDB code 1D5S) \[57\], showing the promiscuous nature of the RCL. Cleavage at the P5/P6 position has resulted in RCL (magenta) insertion into β-sheet A; the \'gap\' at the bottom of β-sheet A is filled with the P5-P1 portion (pale pink) from an RCL from another molecule. **(c)**The structure of an alternative confirmation of SERPINA3 -δ-SERPINA3 (PDB code 1QMN) \[62\]. Four residues of the RCL (magenta) are inserted into the top of β-sheet A. The F-helix (green) has partially unwound and filled the bottom half of β-sheet A. **(d)**Serpins can accept a peptide with the sequence of the RCL (pale pink) into β-sheet A (PDB code 1BR8) \[98\].](gb-2006-7-5-216-4){#F4}
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Function and dysfunction of human serpins

  Serpin      Alternative name(s)                                        Protease target or function                                                                                                        Involvement in disease
  ----------- ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  SERPINA1    Antitrypsin                                                Extracellular; inhibition of neutrophil elastase                                                                                   Deficiency results in emphysema: polymerization and retention in the ER results in cirrhosis \[14,64,65\]
  SERPINA2    Antitrypsin-related protein                                Not characterized, probable pseudogene                                                                                             
  SERPINA3    Antichymotrypsin                                           Extracellular; inhibition of cathepsin G                                                                                           Deficiency results in emphysema (see \[61\] for a review)
  SERPINA4    Kallistatin (PI4)                                          Extracellular, inhibition of kallikrein \[68\]                                                                                     
  SERPINA5    Protein C inhibitor (PAI-3)                                Extracellular; inhibition of active protein C (see \[69\] for a review)                                                            Angioedema
  SERPINA6    Corticosteroid-binding globulin                            Extracellular; non-inhibitory; cortisol binding                                                                                    Deficiency linked to chronic fatigue \[83,84\]
  SERPINA7    Thyroxine-binding globulin                                 Extracellular; non-inhibitory, thyroxine binding                                                                                   Deficiency results in hypothyroidism \[85\]
  SERPINA8    Angiotensinogen                                            Extracellular; non-inhibitory; amino-terminal cleavage by the protease renin results in release of the decapeptide angiotensin I   Certain variants linked to essential hypertension \[86\]
  SERPINA9    Centerin                                                   Extracellular; maintenance of naive B cells \[70\]                                                                                 
  SERPINA10   Protein Z-dependent proteinase inhibitor                   Extracellular; inhibition of activated factor Z and XI                                                                             Deficiency linked to venous thromboembolic disease \[87\]
  SERPINA11   XP_170754.3                                                Not characterized                                                                                                                  
  SERPINA12   Vaspin                                                     Extracellular; insulin-sensitizing adipocytokine \[71\]                                                                            
  SERPINA13   XM_370772                                                  Not characterized                                                                                                                  
  SERPINB1    Monocyte neutrophil elastase inhibitor                     Intracellular; inhibition of neutrophil elastase \[72\]                                                                            
  SERPINB2    Plasminogen activator inhibitor-2 (PAI2)                   Intracellular; inhibition of uPA (see \[73\] for a review)                                                                         
  SERPINB3    Squamous cell carcinoma antigen-1                          Intracellular; cross-class inhibition of cathepsins L and V \[6\]                                                                  
  SERPINB4    Squamous cell carcinoma antigen-2                          Intracellular; cross-class inhibition of cathepsin G and chymase \[74\]                                                            
  SERPINB5    Maspin                                                     Intracellular; non-inhibitory; inhibition of metastasis through uncharacterized mechanism                                          Downregulation and/or intracellular location linked to tumor progression and overall prognosis \[10\]
  SERPINB6    Proteinase inhibitor-6 (PI6)                               Intracellular, inhibition of cathepsin G \[75\]                                                                                    
  SERPINB7    Megsin                                                     Intracellular; megakaryocyte maturation \[76\]                                                                                     IgA nephropathy
  SERPINB8    Cytoplasmic antiproteinase 8 (PI8)                         Intracellular; inhibition of furin \[77\]                                                                                          
  SERPINB9    Cytoplasmic antiproteinase 9 (PI9)                         Intracellular, inhibition of granzyme B \[78\]                                                                                     
  SERPINB10   Bomapin (PI10)                                             Intracellular; inhibition of thrombin and trypsin \[79\]                                                                           
  SERPINB11   Epipin                                                     Intracellular                                                                                                                      
  SERPINB12   Yukopin                                                    Intracellular; inhibition of trypsin \[80\]                                                                                        
  SERPINB13   Headpin (PI13)                                             Intracellular; inhibition of cathepsins L and K                                                                                    
  SERPINC1    Antithrombin                                               Extracellular; thrombin and factor Xa inhibitor                                                                                    Deficiency results in thrombosis (see \[88\] for review)
  SERPIND1    Heparin cofactor II                                        Extracellular; thrombin inhibitor                                                                                                  May contribute to thrombotic risk when combined with other deficiencies \[89\]
  SERPINE1    Plasminogen activator inhibitor I (PAI1)                   Extracellular; inhibitor of thrombin, uPA, tPA and plasmin                                                                         Abnormal bleeding \[90\]
  SERPINE2    Protease nexin I (PI7)                                     Extracellular; inhibition of uPA and tPA                                                                                           
  SERPINE3    Hs.512272                                                  Not characterized                                                                                                                  
  SERPINF1    Pigment epithelium derived factor                          Non-inhibitory; potent anti-angiogenic molecule \[81\]                                                                             
  SERPINF2    Alpha-2-antiplasmin                                        Extracellular; plasmin inhibitor                                                                                                   Unrestrained fibrinolytic activity, bleeding \[91\]
  SERPING1    C1 inhibitor                                               C1 esterase inhibitor                                                                                                              Angioedema \[92\]
  SERPINH1    47kDa heat-shock protein                                   Non-inhibitory molecular Chaperone for collagens \[9\]                                                                             
  SERPINI1    Neuroserpin (PI12)                                         Extracellular; inhibitor of tPA, uPA and plasmin                                                                                   Polymerization results in dementia \[17\]
  SERPINI2    Myoepithelium-derived serine proteinase inhibitor (PI14)   Extracellular; inhibition of cancer metastasis \[82\]                                                                              
